AVR at a glance
Anteris Technologies Global Corp. (AVR, SEC CIK 2011514) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Anteris Technologies Global Corp. (AVR) reported revenue of $1.9 million (down 29.2% from FY2024) and a net loss of $94.1 million. Diluted EPS was -$2.55.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Anteris Technologies Global Corp. (AVR) shares worth $192.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by L1 Capital Pty Ltd on October 5, 2026 of 648,455 shares at $7.51 per share.
- In the last 90 days, AVR insiders reported 4 open-market purchases ($9.7M) and 13 open-market sales ($25.2M) on Form 4, a net sale of $15.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9M
- −29.2% vs prior year
- Insiders · 90 days
- 4 buys · 13 sells
- Net −$15.5M
- 13F holders
- 25 funds
- $192.6M · +1 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $1.0M vs $0.6M YoY, up 63%, driven by tissue-product sales to 4C
- Gross margin generally consistent YoY; operating loss $31.0M vs $20.9M
- Single segment: DurAVR THV System development; 4C tissue sales increased 63% to $1.0M
- Cash $260.9M at June 30; operating cash outflow $49.5M vs $41.0M
- Financing provided $298.6M, including $308.3M net stock proceeds; losses expected near term and cash sufficient for at least 12 months
Risk Factors
- Newly added risk: PARADIGM Trial failure, following FDA IDE approval
- Regulatory risk: FDA approval may be revoked or require costly post-market testing
- Operational risk: Trial delays could prevent DurAVR THV System revenue and profitability
- Compliance risk: FDA enforcement or inquiries could discourage physician adoption
AI summary of the AVR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Supply and quality agreement extended through December 31, 2026, or earlier replacement agreement execution
- Harvey Industries Group remains a key supplier or quality counterpart under unchanged existing terms
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Contingent stock awards require shareholder approval, creating potential dilution and governance risk for investors
- Wayne Paterson awarded 1,200,000 options and 800,000 PSUs; David St Denis awarded 414,000 options and 485,000 PSUs
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Brent Moen appointed CFO effective September 11, 2026, bringing 25+ years’ financial leadership across medical technology companies
- Base salary $475,000 with short-term bonus opportunity up to 50% of salary, prorated for 2026
AI summaries of AVR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVR
Don't miss the next AVR filing
- Alerts as it files. A push when AVR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVR, by share count.
- Ask anything. An AI agent that reads every AVR filing and answers with sources.
AVR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| L1 Capital Pty Ltd | Buy | Oct 5, 2026 | 648,455 | $7.51 |
| L1 Capital Pty Ltd | Buy | Oct 2, 2026 | 236,354 | $7.78 |
| L1 Capital Pty Ltd | Buy | Oct 1, 2026 | 322,940 | $7.60 |
| L1 Capital Pty Ltd | Buy | Sep 30, 2026 | 74,286 | $7.72 |
| Moen Brent | A | Sep 11, 2026 | 90,274 | - |
| L1 Capital Pty Ltd | Sell | Aug 28, 2026 | 7,800 | $8.83 |
| St Denis David | M | Aug 19, 2026 | 60,000 | $5.65 |
| St Denis David | F | Aug 19, 2026 | 45,072 | $9.58 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.7M | $1.9M |
| Operating Income | - | -$78.4M | -$93.9M |
| Net Income | - | -$76.3M | -$94.1M |
| Op. Margin | - | -2899.4% | -4908.2% |
| Net Margin | - | -2822.5% | -4921.3% |
| Balance Sheet | |||
| Total Assets | - | $80.7M | $23.0M |
| Equity | $18.9M | $62.8M | -$93K |
| ROE | - | -121.6% | 101230.1% |
| Per Share | |||
| EPS | - | $-3.68 | $-2.55 |
| Cash Flow | |||
| Operating CF | - | -$61.2M | -$77.8M |
| CapEx | - | $2.3M | $2.0M |
Source: XBRL data in Anteris Technologies Global Corp. (AVR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $192.6M |
| Q1 2026 | 24 | $72.2M |
| Q4 2025 | 17 | $28.3M |
| Q3 2025 | 17 | $29.9M |
| Q2 2025 | 16 | $12.8M |
| Q1 2025 | 13 | $3.6M |
| Q4 2024 | 3 | $6.2M |
- FMR LLC (Fidelity)+3.97M (+137%)
- BlackRock+882.1K (+18%)
- Citadel Advisors LLC+581.2K (+2017%)
- State Street Corp+486.1K (+40%)
- JPMorgan Chase & Co+291.6K (+900%)
- Millennium Management−162.6K (-83%)
- Morgan Stanley−41.0K (-25%)
- Goldman Sachs Group−35.5K (-9%)
- U.S. Bancorp−18 (-34%)
- PNC Financial Services−5 (-33%)
- Ameriprise Financial−653.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 115 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 10, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
AVR SEC filings: frequently asked questions
Are AVR insiders buying or selling?
In the last 90 days, Anteris Technologies Global Corp. (AVR) officers, directors and 10% owners reported 4 open-market purchases worth $9.7 million by 1 insider and 13 open-market sales worth $25.2 million by 1 insider on Form 4, a net sale of $15.5 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AVR stock?
As of June 30, 2026, the largest Anteris Technologies Global Corp. (AVR) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($67.7 million), BlackRock ($56.8 million), State Street Corp ($16.8 million), Vanguard Capital Management LLC ($8.7 million), Northern Trust ($6.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AVR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Anteris Technologies Global Corp. (AVR) reported revenue of $1.9 million (down 29.2% from FY2024) and a net loss of $94.1 million. Diluted EPS was -$2.55. The figures come from the XBRL data in the 10-K.
What did AVR report in its latest 8-K?
Anteris Technologies Global Corp. (AVR) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Supply and quality agreement extended through December 31, 2026, or earlier replacement agreement execution.
What are the latest AVR SEC filings?
Anteris Technologies Global Corp. (AVR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on October 6, 2026.
What is AVR's SEC CIK number?
Anteris Technologies Global Corp. (AVR)'s SEC Central Index Key (CIK) is 2011514. EDGAR lists every AVR filing under that number.
Ask anything about AVR
The research agent reads AVR's filings, financials, insider trades and 13F holders, then answers with sources.